News | September 16, 2009

Lantheus to Study Safety of Novel PET Agent for Heart Failure

September 17, 2009 - Lantheus Medical Imaging Inc. today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.
Heart failure is a serious medical condition, in which the heart muscle progressively loses its ability to pump blood, that affects more than five million people in the United States and results in about 1.1 million hospitalizations and 300,000 deaths each year.1,2 Patients with heart failure are six to nine times more likely than the general population3 to suffer sudden cardiac death as a result of abnormal cardiac neuronal function resulting in a fatal arrhythmia. According to the American Heart Association, the total cost of heart failure is estimated to be $37.2 billion in 2009, putting very significant health and financial burdens on patients, their families and society as a whole.

“Given the high incidence of heart failure and associated deaths, there is a significant need to develop new diagnostic tools to help clinicians improve risk stratification and better identify heart failure patients at risk of arrhythmia and sudden cardiac death who might benefit from direct interventional therapy,” said D. Scott Edwards, vice president, global research and development, Lantheus Medical Imaging, Inc. “We look forward to the Phase 1 trial results and advancing the LMI1195 clinical development program.”

The Phase 1 open-label, non-randomized, single-dose study will be conducted in the United States. The study is designed to estimate the radiation dosimetry of LMI1195 in healthy subjects undergoing a PET scan. The study will also evaluate the safety and tolerability of the tracer, gather pharmacokinetic and metabolic data, and assess PET imaging parameters and image quality.

“The initiation of this study represents an important milestone in our strategy to develop a rich pipeline of diagnostic products to advance patient care,” said Don Kiepert, president and chief executive officer of Lantheus Medical Imaging, Inc. “LMI1195 is our second pipeline product to enter clinical development that uses molecular imaging and PET technology to improve cardiovascular imaging. We’re excited about the promise of this imaging agent to change how heart failure patients are evaluated.”

References:
1. National Heart Lung and Blood Institute, Heart Failure Fact Sheet 2007.

2. American Heart Association,www.americanheart.mediaroom.com

3. American Heart Association. Heart Disease and Stoke Statistics, 2009 Update.

For more information: www.lantheus.com

Related Content

FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Overlay Init